SEC Form 4 · accession 0001209191-17-051748
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ana Ward
Officer — SVP and General Counsel
Period of report
Sep 5, 2017
Accepted (ET)
Sep 6, 2017 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option Grant (Right to Buy)F1 | $8.38 | Sep 5, 2017 | A | 95,000 | A | — | Sep 4, 2027 | Common Stock | 95,000 | 95,000 | D |
Explanation of responses
- F125% of the shares subject to the Stock Option will vest and become exercisable on September 1, 2018 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date.